ValiRx Plc (LON:VAL)‘s stock had its “corporate” rating restated by analysts at Northland Securities in a note issued to investors on Thursday.

Separately, Beaufort Securities reaffirmed a “speculative buy” rating on shares of ValiRx Plc in a research note on Wednesday, September 28th.

Shares of ValiRx Plc (LON:VAL) opened at 7.20 on Thursday. The firm’s 50-day moving average price is GBX 7.57 and its 200-day moving average price is GBX 8.57. ValiRx Plc has a one year low of GBX 5.75 and a one year high of GBX 28.01. The firm’s market capitalization is GBX 3.77 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

ValiRx Plc Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with's FREE daily email newsletter.